Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression. Depression is a mood disorder and a serious medical condition that affects millions of Americans. Depressive symptoms may include loss of interest in things typically enjoyed; decreased energy levels; difficulty concentrating or making decisions; restlessness; and feelings of pessimism, hopelessness, and worthlessness. Treatment-resistant depression is a chronic and severe form of depression characterized by failure to respond to traditional forms of treatment, such as antidepressant medications and electroconvulsive therapy. Treatment-resistant depression significantly impacts quality of life, productivity, and is a major contributor of disability world-wide.

This randomized, double-blind, sham stimulation-controlled, multi-center, prospective, parallel design study used deep brain stimulation technology to test whether active bilateral stimulation can safely and effectively improve depressive symptoms in patients with treatment-resistant depression compared to sham stimulation.

Participants meeting criteria for the study were implanted with the Reclaim DBS System. Participants in the active group, who received active stimulation, were compared to the control group, who received sham stimulation, during the 16-week blinded-treatment phase. All participants were monitored for changes in depressive symptoms. After the blinded-treatment phase, all participants received active stimulation.

Candidates for the trial were adults who had major depressive disorder and had not responded to several treatments for depression. Participants in the study continued to receive their current antidepressant medications while participating in the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility, Safety and Efficacy of Deep Brain Stimulation for Depression

NCT00555698

Depression

COMPLETED EARLY_PHASE1

Deep Brain Stimulation to Relieve Depression

NCT02889250

Treatment Resistant Depression

WITHDRAWN PHASE3

Deep Brain Stimulation for Treatment-Refractory Major Depression

NCT00122031

Depression

COMPLETED PHASE1

Electrical Stimulation of the Internal Capsule for Intractable Depression

NCT01069952

Depression

COMPLETED PHASE2

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

NCT02046330

Major Depressive Disorder Treatment Resistant Depression

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Group - Active Stimulation

Receive active stimulation with Reclaim™ DBS System

Group Type ACTIVE_COMPARATOR

Reclaim™ DBS System

Intervention Type DEVICE

Control Group - Sham Stimulation

Receive sham stimulation with Reclaim™ DBS System

Group Type SHAM_COMPARATOR

Reclaim™ DBS System

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reclaim™ DBS System

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consent to participate in screening and study procedures by signing and dating the Informed Consent Form
* Are diagnosed with major depressive disorder (MDD)
* Have tried at least 4 different treatments, for example antidepressant medications, combinations of antidepressant medications, and/or electroconvulsive therapy (ECT)
* Screening MADRS score ≥ 28
* Have had the current major depressive episode persist for at least 2 years
* Females, if of child-bearing potential, must be using an acceptable method of birth control

Exclusion Criteria

* Females: Currently pregnant
* Currently enrolled in or plan to enroll in any concurrent drug and/or device study that may confound the results of this study
* Have a neurological condition that may jeopardize the safety or the conduct of the study
* Have any medical conditions unsuitable for undergoing DBS surgery

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No